ERA Congress 2026 — Dr Lisa Willcocks (Cambridge University Hospitals, Cambridge, UK) joins us to discuss TURING, a multicentre, double-blind, randomised, placebo-controlled phase III trial evaluating rituximab in adults with nephrotic syndrome secondary to minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS).

TURING randomised 130–150 adults presenting with new or relapsing MCD/FSGS across UK renal units to receive either rituximab (two 1g infusions two weeks apart) or placebo, with all participants treated with glucocorticoids per KDIGO guidance and prednisolone withdrawn according to a pre-specified regimen. Those in remission at six months received a further dose of trial drug, while participants randomised to placebo who relapsed were offered open-label rituximab. The primary endpoint was time from remission to relapse, with secondary endpoints spanning safety, NHS and societal resource use and cost, achievement of partial and complete remission, preservation of renal function, and patient health status.

Interview Questions:

1. What is the current treatment landscape for minimal change disease and FSGS, and what unmet need prompted a randomised trial of rituximab?
2. What were the aims of the TURING trial, and how was the study designed to address them?
3. What were your key findings?
4. What are the clinical implications of these findings?
5. What are your key take-home messages for clinicians?
6. What are the next steps for this research?

Recorded on-site at ERA Congress 2026, Glasgow.
Editors: Jordan Rance
Videographer: David Ben-Harosh
Support: This is an independent interview produced by Radcliffe Cardiology.